Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE58.7400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots23.5000/ 2
- Ask / Lots60.0000/ 1
- Open / Previous Close--- / 58.7400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 2022 | 57.945 |
| 09:34 ET | 150 | 57.45 |
| 09:38 ET | 1230 | 58.72 |
| 09:39 ET | 100 | 58.51 |
| 09:43 ET | 349 | 58.76 |
| 09:45 ET | 100 | 58.99 |
| 09:48 ET | 4556 | 59.99 |
| 09:50 ET | 4779 | 60.07 |
| 09:52 ET | 100 | 59.98 |
| 09:54 ET | 1042 | 59.75 |
| 09:57 ET | 100 | 59.65 |
| 09:59 ET | 1821 | 59.34 |
| 10:01 ET | 200 | 59.325 |
| 10:03 ET | 100 | 59.305 |
| 10:06 ET | 2025 | 59.305 |
| 10:08 ET | 1300 | 59.305 |
| 10:10 ET | 662 | 59.265 |
| 10:12 ET | 2354 | 59.345 |
| 10:14 ET | 100 | 59.335 |
| 10:15 ET | 100 | 59.255 |
| 10:17 ET | 1158 | 59.235 |
| 10:19 ET | 1882 | 59.185 |
| 10:21 ET | 1000 | 59.035 |
| 10:24 ET | 500 | 59.045 |
| 10:26 ET | 2500 | 59.105 |
| 10:28 ET | 100 | 59.115 |
| 10:30 ET | 1256 | 59.52 |
| 10:32 ET | 2825 | 59.57 |
| 10:33 ET | 220 | 59.415 |
| 10:35 ET | 100 | 59.43 |
| 10:37 ET | 100 | 59.415 |
| 10:42 ET | 100 | 59.265 |
| 10:44 ET | 2900 | 59.18 |
| 10:48 ET | 100 | 59.125 |
| 10:55 ET | 700 | 59.13 |
| 10:57 ET | 3181 | 59.09 |
| 11:02 ET | 455 | 59.12 |
| 11:04 ET | 1000 | 59.32 |
| 11:06 ET | 200 | 59.26 |
| 11:08 ET | 1030 | 59.29 |
| 11:18 ET | 200 | 59.12 |
| 11:20 ET | 1287 | 59.37 |
| 11:22 ET | 1346 | 59.31 |
| 11:24 ET | 100 | 59.45 |
| 11:26 ET | 613 | 59.34 |
| 11:27 ET | 375 | 59.3 |
| 11:29 ET | 400 | 59.35 |
| 11:33 ET | 200 | 59.34 |
| 11:36 ET | 200 | 59.265 |
| 11:38 ET | 200 | 59.33 |
| 11:40 ET | 1910 | 59.11 |
| 11:42 ET | 1600 | 59.015 |
| 11:44 ET | 200 | 59.02 |
| 11:45 ET | 900 | 59.04 |
| 11:47 ET | 200 | 59.04 |
| 11:51 ET | 100 | 59.12 |
| 11:54 ET | 100 | 59.035 |
| 12:00 ET | 100 | 59.14 |
| 12:02 ET | 100 | 59.03 |
| 12:05 ET | 200 | 59.04 |
| 12:07 ET | 700 | 58.955 |
| 12:09 ET | 131 | 58.965 |
| 12:12 ET | 533 | 58.85 |
| 12:14 ET | 150 | 58.85 |
| 12:16 ET | 450 | 58.87 |
| 12:18 ET | 986 | 58.93 |
| 12:20 ET | 1200 | 58.86 |
| 12:21 ET | 1640 | 58.86 |
| 12:23 ET | 500 | 58.87 |
| 12:25 ET | 200 | 58.79 |
| 12:27 ET | 573 | 58.84 |
| 12:30 ET | 500 | 58.84 |
| 12:32 ET | 668 | 58.95 |
| 12:36 ET | 1000 | 58.69 |
| 12:38 ET | 2938 | 58.74 |
| 12:39 ET | 300 | 58.73 |
| 12:41 ET | 4303 | 58.92 |
| 12:43 ET | 100 | 58.8 |
| 12:50 ET | 100 | 58.92 |
| 12:54 ET | 100 | 58.91 |
| 12:57 ET | 603 | 58.765 |
| 12:59 ET | 635 | 58.785 |
| 01:01 ET | 1056 | 58.85 |
| 01:03 ET | 204 | 58.78 |
| 01:06 ET | 100 | 58.78 |
| 01:08 ET | 1328 | 58.525 |
| 01:12 ET | 100 | 58.33 |
| 01:14 ET | 256 | 58.34 |
| 01:15 ET | 100 | 58.09 |
| 01:19 ET | 600 | 58.1 |
| 01:28 ET | 200 | 58 |
| 01:32 ET | 1086 | 57.97 |
| 01:33 ET | 100 | 57.97 |
| 01:35 ET | 1096 | 58.09 |
| 01:39 ET | 100 | 58.19 |
| 01:44 ET | 100 | 58.04 |
| 01:51 ET | 100 | 58.02 |
| 01:53 ET | 1000 | 58.38 |
| 01:57 ET | 1556 | 58.33 |
| 02:00 ET | 200 | 58.32 |
| 02:08 ET | 2322 | 58.29 |
| 02:11 ET | 1390 | 58.38 |
| 02:13 ET | 800 | 58.175 |
| 02:15 ET | 300 | 57.97 |
| 02:18 ET | 100 | 57.89 |
| 02:20 ET | 3900 | 57.835 |
| 02:22 ET | 2950 | 57.605 |
| 02:24 ET | 700 | 57.49 |
| 02:26 ET | 100 | 57.43 |
| 02:27 ET | 1122 | 57.61 |
| 02:31 ET | 200 | 57.615 |
| 02:33 ET | 200 | 57.6 |
| 02:47 ET | 450 | 57.82 |
| 02:54 ET | 1700 | 58.38 |
| 02:58 ET | 100 | 58.13 |
| 03:02 ET | 923 | 57.97 |
| 03:05 ET | 3564 | 58.01 |
| 03:09 ET | 400 | 58.09 |
| 03:14 ET | 100 | 58.175 |
| 03:16 ET | 674 | 58.17 |
| 03:18 ET | 100 | 58.28 |
| 03:21 ET | 3645 | 58.2 |
| 03:23 ET | 100 | 58.23 |
| 03:27 ET | 100 | 58.235 |
| 03:30 ET | 100 | 58.17 |
| 03:32 ET | 100 | 58.265 |
| 03:34 ET | 700 | 58.14 |
| 03:36 ET | 2700 | 58.185 |
| 03:38 ET | 321 | 58.23 |
| 03:39 ET | 300 | 58.265 |
| 03:41 ET | 205 | 58.16 |
| 03:48 ET | 581 | 58.155 |
| 03:50 ET | 3000 | 58.17 |
| 03:52 ET | 1700 | 58.4528 |
| 03:54 ET | 8431 | 58.5325 |
| 03:56 ET | 5394 | 58.92 |
| 03:57 ET | 2297 | 58.89 |
| 03:59 ET | 182023 | 58.74 |
Sep 12, 2024
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit, from 7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 9, 2024
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesPress Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.4B | -26.2x | --- |
Dyne Therapeutics Inc | 3.6B | -10.0x | --- |
MoonLake Immunotherapeutics | 3.2B | -55.8x | --- |
Merus NV | 3.4B | -17.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.4x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -26.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
